Interleukin-1 increases expression of the LYT-10 (NFκB2) proto-oncogene/transcription factor in renal cell carcinoma lines

Journal of Laboratory and Clinical Medicine

Volumn 131, Issue 3, 1998, Pages 261-268

  Kurzrock, Razelle ^a,b,c   Estrov, Zeev ^a,b   Ku, Stella ^a,b   Leonard, Margaret ^a,b   Talpaz, Moshe ^a,b  

^a Houston ^*

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME ABERRATION; CLONE; GENE EXPRESSION REGULATION;

EID: 0032033413     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(98)90099-3     Document Type: Article

References (49)

1. Potter DA, Larson CJ, Eckes P, Schmid RM, Nabel GJ, Verdine GL, et al. Purification of the major histocompatibility complex class I transcription factor H2TF1, the full-length product of the nfkb2 gene. J Biol Chem 1993;288:18882-90.
2. Swingler S, Morris A, Easton A. Tumour necrosis factor α and interleukin-1β induce specific sub units of NFκB to bind the HIV-1 enhancer: characterization of transcription factors controlling human immunodeficiency virus type 1 gene expression in neural cells. Biochem Biophys Res Commun 1994;203:623-30.
3. Swingler S, Easton A, Morris A. Cytokine augmentation of HIV-1 LTR-driven gene expression in neural cells. AIDS Res Hum Retroviruses 1992;8:487-93.
4. LaRosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-κB Rel family of transcription factors. Mol Cell Biol 1994;14:1039-44.
5. Matsusaka T, Fujidawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, et al. Transcription factors of NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 1993;90:10193-7.
6. Mori N, Shirakawa F, Shimizu H, Murakami S, Oda S, Yamamoto K-I, et al. Transcriptional regulation of the human interleukin-6 gene promoter in human T-cell leukemia virus type I-infected T-cell lines: evidence for the involvement of the NF-κB. Blood 1994;84:2904-11.
7. Wu H, Lozano G. NF-κB activation of p53: a potential mechanism for suppressing cell growth in response to stress. J Biol Chem 1994;269:20067-74.
8. Lenardo MJ, Baltimore D. NF-κB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58:227-9.
9. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1988;242:540-5.
10. Chang C-C, Zhang J, Lombardi L, Neri A, Dalla-Favera R. Mechanism of expression and role in transcriptional control of the proto-oncogene NFκB-2/LYT-10. Oncogene 1994;9: 923-33.
11. Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck R-P, et al. A novel mitogen-inducible gene product related to p50/p105-NF-κB participates in transactivation through a κB site. Mol Cell Biol 1992;12:685-95.
12. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP, Baltimore D. Cloning of the p50 DNA binding subunit of NF-κB: homology to rel and dorsal. Cell 1990;62:1019-29.
13. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell 1995;80:529-432.
14. Neri A, Chang C-C, Lombardi L, Salina M, Corradini P, Mailo AT, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 1991;67:1075-87.
15. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, et al. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies. Oncogene 1992;8:2839-45.
16. Ruben SM, Dillon PJ, Schreck R, Henkel T, Chen C-H, Maher M, et al. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-κB. Science 1991;251:1490-3.
17. Nolan GP, Ghosh S, Liou Ho-C, Tempst P, Baltimore D. DNA binding and IκB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide. Cell 1991;64:961-9.
18. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83:1668-72.
19. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250: 607-10.
20. Blay J-Y, Negrier S, Combaret V, Merrouche Y, Mercatello A, Moskovtchenko JF, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
21. Thomas PS. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A 1980;77:5201-5.
22. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chromic myelogenous leukemia progression. Blood 1991;78:2400-6.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-54.
24. Neumann JR, Morency CA, Russian O. A novel rapid assay for chloramphenicol acetyltransferase gene expression. Biotechniques 1992;5:444-8.
25. Ray A, Tatter SB, May LT, Sehgal PB. Activation of the human β2-interferon/hepatocyte-stimulating factor/interleukin-6 promoter by cytokines, viruses, and second messenger agonists. Proc Natl Acad Sci U S A 1988;85:6701-5.
26. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol Cell Biol 1990;10:2327-34.
27. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
28. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990;9:1897-906.
29. Akira S, Isshiki H, Nakajima T, Kinoshita S, Nishio Y, Hashimoto S, et al. A nuclear factor for the IL-6 gene (NF-IL6). Chem Immunol 1992;51:299-332.
30. Sen R, Baltimore D. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell 1986;47:921-8.
31. Hohmann H-P, Remy R, Schiedereit C, van Loon APM. Maintenance of NFκB activity is dependent on protein synthesis and the continuous presence of external stimuli. Mol Cell Biol 1991;11:259-66.
32. Read MA, Whitley MZ, Williams AJ, Collins T. NF-κB and IκBα: an inducible regulatory system in endothelial activation. J Exp Med 1994;179:503-12.
33. Tzen CY, Cox RL, Scott RE. Coordinate induction of I kappa B alpha and NF kappa B genes. Exp Cell Res 1994; 211:12-6.
34. Stylianou E, O'Neill LAJ, Rawlinson L, Edbrooke MR, Woo P, Saklatvala J. Interleukin-1 induces NF-κB through its type I but not its type II receptor in lymphocytes. J Biol Chem 1992;267:15836-41.
35. Ng SB, Tan YH, Guy GR. Differential infection of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 1994;269:19021-7.
36. Beg AA, Baldwin AS Jr. Activation of multiple NF-κB/Rel DNA-binding complexes by tumor necrosis factor. Oncogene 1994;9:1487-92.
37. Ghosh S, Baltimore D. Activation in vitro of NF-κB by phosphorylation or its inhibitor IκB. Nature 1990;344:678-82.
38. Hohmann H-P, Remy R, Poschl B, van Loon APM. Tumor necrosis factors-α and -β bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-κB at low receptor occupancy and within minutes after receptor binding. J Biol Chem 1990; 265:15183-8.
39. Ten RM, Paya CV, Israel N, Le Bail O, Mattel M-G, Virelizier J-L, et al. The characterization of the promoter of the gene encoding the p50 subunit of NF-κB indicates that it participated in its own regulation. EMBO J 1992;11:195-203.
40. Bours V, Villalobos J, Burd RP, Kelly K, Sievenlist U. Cloning of a mitogen-inducible gene encoding a κB DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature 1990;348:76-80.
41. Liptay S, Schmid RM, Nabel EG, Navel GJ. Transcriptional regulation of NF-κB2: evidence for κB-mediated positive and negative autoregulation. Mol Cell Biol 1994;14:7695-703.
42. Lombardi L, Ciana P, Cappellini C, Trecca D, Guerrini L, Migliazza A, et al. Structural and functional characterization of the promoter regions of the NFκB2 gene. Nucleic Acids Res 1995;23:2328-36.
43. Pan J, McEver RP. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-κB/Rel family. J Biol Chem 1995;270:23077-83.
44. Naumann M, Nieters A, Hatada EN, Scheidereit C. NF-κB precursor p 100 inhibits nuclear translocation and DNA binding of NF-κB/rel-factors. Oncogene 1993;8:2275-81.
45. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, et al. The oncoprotein bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 1993;72:729-39.
46. Bours V, Defardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-9.
47. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999-1003.
48. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, et al. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A 1993;90:9901-05.
49. Godambe SA, Cahaplin DD, Takova T, Bellone C. An NF-IL6 sequences near the transcriptional initiation site is necessary for the lipopolysaccharide induction of murine interleukin-1β. DNA Cell Biol 1994;13:561-9.